Eli Lilly - Zyprexa

Company: Eli Lilly
Amount: $1.4 billion
Drug: Zyprexa
Year: 2009

When Eli Lilly ($LLY) announced its $1.415 billion settlement with the Justice Department, it was the largest amount ever paid by any one defendant. It would keep that record for only 8 months, till Pfizer's Bextra deal went public. But at the time, Justice officials bragged about the historic nature of the agreement: "the largest criminal fine for an individual corporation ever imposed in a United States criminal prosecution of any kind," the department's release crowed.

More than $1.4 billion may seem like a lot less today, with an impending settlement of up to $2.2 billion from Johnson & Johnson ($JNJ) and a forthcoming $3 billion agreement with GlaxoSmithKline ($GSK). But in January 2009, it outranked the previous top pharma settlement--TAP Pharmaceuticals, $875 million, 2001--by more than $500 million. 

Among the allegations: That Lilly pushed Zyprexa for children and for elderly dementia patients, both off-label uses. That it made particular efforts to push Zyprexa in long-term care facilities and nursing homes. And that Lilly aimed to make Zyprexa a primary care drug, despite the fact that it was only approved to treat two disorders--schizophrenia and bipolar disorder--typically not handled by primary-care doctors.

Lilly pleaded guilty to a misdemeanor misbranding charge for promoting Zyprexa off-label between 1999 and 2001, and for that charge it paid a fine of $515 million and forfeited $100 million. The civil wrap-up included $438 million for the feds and $362 million to states that agreed to settle.

In announcing the settlement, Lilly CEO John Lechleiter--fairly new on the job at the time--pledged personal commitment to "the highest standards of conduct" for everyone at Lilly and promised new programs to make sure everyone followed the rules. One visible result of the settlement: As required by the corporate integrity agreement, Lilly posts on its website information about payments or perks provided to doctors, in the original physician sunshine database.

Eli Lilly - Zyprexa
Read more on

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.